JCDSA  Vol.3 No.2 A , June 2013
Melanoma Immunotherapy: Overcoming Obstacles to Augment Anti-Tumor Immune Responses
Abstract

Melanoma is the most aggressive form of skin cancer and accounts for the vast majority of skin cancer-related deaths. Its ability to metastasize quickly, often before diagnosis, makes this cancer difficult to treat with traditional therapies. The identification of anti-melanoma immune responses in patients and the discovery of tumor antigens targeted by these immune responses have paved the way for immunotherapy as a novel approach to treating this cancer. In this review, the major immunotherapies targeting these melanoma tumor antigens are discussed. The advantages and limitations of peptide-, protein-, and gene-based vaccination maneuvers and adoptive cell transfer therapies are emphasized. Recent insights into melanoma immune evasion strategies are also highlighted, with particular focus on how our increasing knowledge of tumor/immune cell interactions is driving the development of novel immunotherapeutic strategies for the treatment of melanoma.


Cite this paper
K. Hargadon, "Melanoma Immunotherapy: Overcoming Obstacles to Augment Anti-Tumor Immune Responses," Journal of Cosmetics, Dermatological Sciences and Applications, Vol. 3 No. 2, 2013, pp. 7-27. doi: 10.4236/jcdsa.2013.32A002.
References

[1]   A. M. Leung, D. M. Hari and D. L. Morton, “Surgery for Distant Melanoma Metastasis,” The Cancer Journal, Vol. 18, No. 2, 2012, pp. 176-184. doi:10.1097/PPO.0b013e31824bc981

[2]   J. Ferlay, H.-R. Shin, F. Bray, D. Forman, C. Mathers and D. M. Parkin, “Estimates of Worldwide Burden of Cancer in 2008: GLOBOCAN 2008,” International Journal of Cancer, Vol. 127, No. 12, 2010, pp. 2893-2917. doi:10.1002/ijc.25516

[3]   E. Losina, R. P. Walensky, A. C. Geller, F. C. Beddingfield, L. L. Wolf, B. A. Gilchrest and K. A. Freedberg, “Visual Screening for Malignant Melanoma: A Cost-Effectiveness Analysis,” Archives of Dermatology, Vol. 143, No. 1, 2007, pp. 21-28. doi:10.1001/archderm.143.1.21

[4]   B. K. Edwards, M. L. Brown, P. A. Wingo, H. L. Howe, E. Ward, L. A. G. Ries, D. Schrag, P. M. Jamison, A. Jemal, X. C. Wu, C. Friedman, L. Harlan, J. Warren, R. N. Anderson and L. W. Pickly, “Annual Report to the Nation on the Status of Cancer, 1975-2002, Featuring Population Based Trends in Cancer Treatment,” Journal of the National Cancer Institute, Vol. 97, No. 19, 2005, pp. 1407-1427. doi:10.1093/jnci/dji289

[5]   A. Jemal, T. Murray, A. Ghafoor, E. Ward and M. J. Thun, “Cancer Statistics, 2003,” CA: A Cancer Journal for Clinicians, Vol. 53, No. 1, 2003, pp. 5-26. doi:10.3322/canjclin.53.1.5

[6]   N. Howlader, A. M. Noone, M. Krapcho, N. Neyman, R. Aminou, S. F. Altekruse, C. L. Kosary, J. Ruhl, Z. Tatalovich, H. Cho, A. Mariotto, M. P. Eisner, D. R. Lewis, H. S. Chen, E. J. Feuer and K. A. Cronin, “SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations),” National Cancer Institute, Bethesda, 2012. http://seer.cancer.gov/csr/1975_2009_pops09/

[7]   A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu and M. J. Thun, “Cancer Statistics: 2009,” A Cancer Journal for Clinicians, Vol. 59, No. 4, 2009, pp. 225-249. doi:10.3322/caac.20006

[8]   A. I. Riker, T. Zea and T. Trinh, “The Epidemiology, Prevention, and Detection of Melanoma,” The Ochsner Journal, Vol. 10, No. 2, 2010, pp. 56-65.

[9]   F. J. Lejeune, “The Impact of Surgery on the Course of Melanoma,” Recent Results in Cancer Research, Vol. 160, 2002, pp. 151-157. doi:10.1007/978-3-642-59410-6_18

[10]   American Cancer Society, “Cancer Facts & Figures— 2008,” 2008.

[11]   M. B. Atkins, J. Hsu, S. Lee, G. I. Cohen, L. E. Flaherty, J. A. Sosman, V. K. Sondak and J. M. Kirkwood, “Phase III Trial Comparing Concurrent Biochemotherapy with Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon alfa-2b with Cisplatin, Vinblastine, and Dacarbazine Alone in Patients with Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group,” Journal of Clinical Oncology, Vol. 26, No. 35, 2008, pp. 5748-5754. doi:10.1200/JCO.2008.17.5448

[12]   M. B. Atkins, J. A. Sosman, S. Agarwala, T. Logan, J. I. Clark, M. S. Ernstoff, D. Lawson, J. P. Dutcher, G. Weiss, B. Curti and K. A. Margolin, “Temozolomide, Thalidomide, and Whole Brain Radiation Therapy for Patients with Brain Metastasis from Metastatic Melanoma: A Phase II Cytokine Working Group Study,” Cancer, Vol. 113, No. 8, 2008, pp. 2139-2145. doi:10.1002/cncr.23805

[13]   K. H. Burdick and W. A. Hawk, “Vitiligo in a Case of Vaccinia Virus-Treated Melanoma,” Cancer, Vol. 17, No. 6, 1964, pp.708-712. doi:10.1002/1097-0142(196406)17:6<708::AID-CNCR2820170604>3.0.CO;2-3

[14]   J. L. Smith, Jr. and J. S. Stehlin, Jr., “Spontaneous Regression of Primary Malignant Melanomas with Regional Metastases,” Cancer, Vol. 18, No. 11, 1965, pp. 1399-1415. doi:10.1002/1097-0142(196511)18:11<1399::AID-CNCR2820181104>3.0.CO;2-R

[15]   J. J. Nordlund, J. M. Kirkwood, B. M. Forget, G. Milton, D. M. Albert and A. B. Lerner, “Vitiligo in Patients with Metastatic Melanoma: A Good Prognostic Sign,” Journal of the American Academy of Dermatology, Vol. 9, No, 5, 1983, pp. 689-696. doi:10.1016/S0190-9622(83)70182-9

[16]   J. C. Bystryn, D. Rigel, R. J. Friedman and A. Kopf, “Prognostic Significance of Hypopigmentation in Malignant Melanoma,” Archives of Dermatology, Vol. 123, No. 8, 1987, pp. 1053-1055. doi:10.1001/archderm.1987.01660320095019

[17]   P. Quaglino, F. Marenco, S. Osella-Abate, N. Cappello, M. Ortoncelli, B. Salomone, M. T. Fierro, P. Savoia and M. G. Bernengo, “Vitiligo Is an Independent Favourable Prognostic Factor in Stage III and IV Metastatic Melanoma Patients: Results from a Single-Institution Hospital-Based Observational Cohort Study,” Annals of Oncology, Vol. 21, No. 2, 2010, pp. 409-414. doi:10.1093/annonc/mdp325

[18]   M. Hérin, C. Lemoine, P. Weynants, F. Vessière, A. van Pel, A. Knuth, R. Devos and T. Boon, “Production of Stable Cytolytic T-Cell Clones Directed against Autologous Human Melanoma,” International Journal of Cancer, Vol. 39, No. 3, 1987, pp. 390-396. doi:10.1002/ijc.2910390320

[19]   L. M. Muul, P. J. Spiess, E. P. Director and S. A. Rosenberg, “Identification of Specific Cytolytic Immune Responses Against Autologous Tumor in Humans Bearing Malignant Melanoma,” The Journal of Immunology, Vol. 138, No. 3, 1987, pp. 989-995.

[20]   A. Anichini, C. Maccalli, R. Mortarini, S. Salvi, A. Mazzocchi, P. Squarcina, M. Herlyn and G. Parmiani, “Melanoma Cells and Normal Melanocytes Share Antigens Recognized by HLA-A2-Restricted Cytotoxic T Cell Clones from Melanoma Patients,” The Journal of Experimental Medicine, Vol. 177, No. 4, 1993, pp. 989-998. doi:10.1084/jem.177.4.989

[21]   P. van der Bruggen, C. Traversari, P. Chomez, C. Lurquin, E. de Plaen, B. van den Eynde, A. Knuth and T. Boon, “A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma,” Science, Vol. 254, No. 5038, 1991, pp. 1643-1647. doi:10.1126/science.1840703

[22]   O. L. Cabellero and Y.-T. Chen, “Cancer/Testis (CT) Antigens: Potential Targets for Immunotherapy,” Cancer Science, Vol. 100, No. 11, 2009, pp. 2014-2021. doi:10.1111/j.1349-7006.2009.01303.x

[23]   Y. Kawakami, S. Eliyahu, C. H. Delgado, P. F. Robbins, L. Rivoltini, S. L. Topalian, T. Miki and S. A. Rosenberg, “Cloning of the Gene Coding for a Shared Human Melanoma Antigen Recognized by Autologous T Cells Infiltrating into Tumor,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 91, No. 9, 1994, pp. 3515-3519. doi:10.1073/pnas.91.9.3515

[24]   Y. Kawakami, S. Eliyahu, C. H. Delgado, P. F. Robbins, K. Sakaguchi, E. Appell, J. R. Yannelli, G. J. Adema, T. Miki and S. A. Rosenberg, “Identification of a Human Melanoma Antigen Recognized by Tumor-Infiltrating Lymphocytes Associated with in Vivo Tumor Rejection,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 91, No. 14, 1994, pp. 6458-6462. doi:10.1073/pnas.91.14.6458

[25]   R.-F. Wang, P. F. Robbins, Y. Kawakami, X. Q. Kang and S. A. Rosenberg, “Identification of a Gene Encoding a Melanoma Tumor Antigen Recognized by HLA-A31-Restricted Tumor-Infiltrating Lymphocytes,” The Journal of Experimental Medicine, Vol. 181, No. 2, 1995, pp. 799-904. doi:10.1084/jem.181.2.799

[26]   R.-F. Wang, E. Appell, Y. Kawakam, X. Kang and S. A. Rosenberg, “Identification of TRP-2 as a Human Tumor Antigen Recognized by Cytotoxic T Lymphocytes,” The Journal of Experimental Medicine, Vol. 184, No. 6, 1996, pp. 2207-2216. doi:10.1084/jem.184.6.2207

[27]   V. Brichard, A. van Pel, T. Wolfel, C. Wolfel, E. de Plaen, B. Lethe, P. Culie and T. Boon, “The Tyrosinase Gene Codes for an Antigen Recognized by Autologous Cytolytic T Lymphocytes on HLA-A2 Melanomas,” The Journal of Experimental Medicine, Vol. 178, No. 2, 1993, pp. 489-495. doi:10.1084/jem.178.2.489

[28]   M. B. Bloom, D. Perry-Lalley, P. F. Robbins, Y. Li, M. El-Gamil, S. A. Rosenberg and J. C. Yang, “Identification of Tyrosinase-Related Protein 2 as a Tumor Rejection Antigen for the B16 Melanoma,” The Journal of Experimental Medicine, Vol. 185, No. 3, 1997, pp. 453-460. doi:10.1084/jem.185.3.453

[29]   V. H. Engelhard, T. N. Bullock, T. A. Colella and D. W. Mullins, “Direct Identification of Human Tumor-Associated Peptide Ags and a Preclinical Model to Evaluate Their Use,” The Cancer Journal, Vol. 6, No. 3, 2000, pp. S272-S280.

[30]   D. W. Mullins, T. N. J. Bullock, T. A. Colella, V. V. Robila and V. H. Engelhard, “Immune Responses to the HLAA*0201-Restricted Epitopes of Tyrosinase and Glycoprotein 100 Enable Control of Melanoma Outgrowth in HLA-A*0201-Transgenic Mice,” The Journal of Immunology, Vol. 167, No. 9, 2001, pp. 4853-4860.

[31]   K. M. Hargadon, C. C. Brinkman, S. L. Sheasley-O’neill, L. A. Nichols, T. N. Bullock and V. H. Engelhard, “Incomplete Differentiation of Antigen-Specific CD8 T cells in Tumor-Draining Lymph Nodes,” The Journal of Immunology, Vol. 177, No. 9, 2006, pp. 6081-6090.

[32]   T. A. Colella, T. N. J. Bullock, L. B. Russel, D. W. Mullins, W. W. Overwijk, C. J. Luckey, R. A. Pierce, N. P. Restifo and V. H. Engelhard, “Self-Tolerance to the Murine Homologue of a Tyrosinase-Derived Melanoma Antigen: Implications for Tumor Immunotherapy,” The Journal of Experimental Medicine, Vol. 191, No. 7, 2000, pp. 1221-1232. doi:10.1084/jem.191.7.1221

[33]   M. W. J. Schreurs, A. A. O Eggert, A. J. de Boer, J. L. M. Vissers, T. van Hall, R. Offringa, C. G. Figdor and G. J. Adema, “Dendritic Cells Break Tolerance and Induce Protective Immunity against a Melanocyte Differentiation Antigen in an Autologous Melanoma Model,” Cancer Research, Vol. 60, No. 24, 2000, pp. 6995-7001.

[34]   R. P. M. Sutmuller, L. M. van Duivenvoorde, A. van Elsas, T. N. M. Shumacher, M. A. Wildenberg, J. P. Allison, R. E. M. Toes, R. Offringa and C. J. M. Melief, “Synergism of Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade and Depletion of CD25+ Regulatory T Cells in Suppression of Autoreactive Cytotoxic T Lymphocyte Responses,” The Journal of Experimental Medicine, Vol. 194, No. 6, 2001, pp. 823-832. doi:10.1084/jem.194.6.823

[35]   D. W. Mullins, S. L. Sheasley, R. M. Ream, T. N. Bullock, Y. X. Fu and V. H. Engelhard, “Route of Immunization with Peptide-Pulsed Dendritic Cells Controls the Distribution of Memory and Effector T cells in Lymphoid Tissues and Determines the Pattern of Regional Tumor Control,” The Journal of Experimental Medicine, Vol. 198, No. 7, 2003, pp. 1023-1034. doi:10.1084/jem.20021348

[36]   T. Wolfel, M. Hauer, J. Schneider, M. Serrano, C. Wolfel, E. Klehmann-Hieb, E. de Plaen, T. Hankeln, K. H. Meyer zum Buschenfelde and D. Beach, “A p16INK4a-Insensitive CDK4 Mutant Targeted by Cytoloytic T Lymphocytes in a Human Melanoma,” Science, Vol. 269, No. 5228, 1995, pp. 1281-1284. doi:10.1126/science.7652577

[37]   P. F. Robbins, M. El-Gamil, Y. F. Li, Y. Kawakami, D. Loftus, E. Appella and S. A. Rosenberg, “A Mutated BetaCatenin Gene Encodes a Melanoma-Specific Antigen Recognized by Tumor Infiltrating Lymphocytes,” The Journal of Experimental Medicine, Vol. 183, No. 3, 1996, pp. 1185-1192. doi:10.1084/jem.183.3.1185

[38]   P. G. Coulie, F. Lehmann, B. Lethe, J. Herman, C. Lurquin, M. Andrawiss and T. Boon, “A Mutated Intron Sequence Codes for an Antigenic Peptide Recognized by Cytolytic T Lymphocytes on a Human Melanoma,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 92, No. 17, 1995, pp. 7976-7980.doi:10.1073/pnas.92.17.7976

[39]   R.-F. Wang, X. Wang, A. C. Atwood, S. L. Topalian and S. A. Rosenberg, “Cloning Genes Encoding MHC Class II-Restricted Antigens: Mutated CDC27 as a Tumor Antigen,” Science, Vol. 284, No. 5418, 1999, pp. 1351-1354. doi:10.1126/science.284.5418.1351

[40]   R.-F. Wang, X. Wang and S. A. Rosenberg, “Identification of a Novel Major Histocompatibility Complex Class II-Restricted Tumor Antigen Resulting from a Chromosomal Rearrangement Recognized by CD4+ T Cells,” The Journal of Experimental Medicine, Vol. 189, No. 10, 1999, pp. 1659-1668. doi:10.1084/jem.189.10.1659

[41]   A. L. Zarling, J. M. Polefrone, A. M. Evans, L. M. Mikesh, J. Shabanowitz, S. T. Lewis, V. H. Engelhard and D. F. Hunt, “Identification of Class I MHC-Associated Phosphopeptides as Targets for Cancer Immunotherapy,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, No. 40, 2006, pp. 14889-14894.doi:10.1073/pnas.0604045103

[42]   F. R. Depontieu, J. Qian, A. L. Zarling, T. L. McMiller, T. M. Salay, A. Norris, A. M. English, J. Shabanowitz, V. H. Engelhard, D. F. Hunt and S. L. Topalian, “Identification of Tumor-Associated, MHC Class II-Restricted Phosphopeptides as Targets of Immunotherapy,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 106, No. 29, 2009, pp. 12073-12078. doi:10.1073/pnas.0903852106

[43]   M. Marchand, P. Weynants, E. Rankin, F. Arienti, F. Belli, G. Parmiani, N. Cascinelli, A. Bourlond, R. Vanwijck, Y. Humblet, J.-L. Canon, C. Laurent, J.-M. Naeyaert, R. Plagne, R. Deraemaeker, A. Knuth, E. Jager, F. Brasseur, J. Herman, P. G. Couiae and T. Boon, “Tumor Regression Responses in Melanoma Patients Treated with a Peptide Encoded by Gene MAGE-3,” International Journal of Cancer, Vol. 63, No. 6, 1995, pp. 883-885. doi:10.1002/ijc.2910630622

[44]   J. N. Cormier, M. L. Salgaller, T. Prevette, K. C. Barracchini, L. Rivoltini, N. P. Restifo, S. A. Rosenberg and F. M. Marincola, “Enhancement of Cellular Immunity in Melanoma Patients Immunized with a Peptide from MART1/Melan A,” The Cancer Journal from Scientific American,” Vol. 3, No. 1, 1997, pp. 37-44.

[45]   F. Wang, E. Bade, C. Kuniyoshi, L. Spears, G. Jeffery, V. Marty, S. Groshen and J. Weber, “Phase I Trial of a MART-1 Peptide Vaccine with Incomplete Freund’s Adjuvant for Resected High-Risk Melanoma,” Clinical Cancer Research, Vol. 5, No. 10, 1999, pp. 2756-2765.

[46]   S. A. Rosenberg, J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, J. R. Wunderlich, M. R. Parkhurst, Y. Kawakami, C. A. Seipp, J. H. Einhorn and D. E. White, “Immunologic and Therapeutic Evaluation of a Synthetic Peptide Vaccine for the Treatment of Patients with Metastatic Melanoma,” Nature Medicine, Vol. 4, No. 3, 1998, pp. 321-327. doi:10.1038/nm0398-321

[47]   J. W. Smith II, E. B. Walker, B. A. Fox, D. Haley, K. P. Wisner, T. Doran, B. Fisher, L. Justice, W. Wood, J. Vetto, H. Maecker, A. Dols, S. Meijer, H.-M. Hu, P. Romero, W. G. Alvord and W. J. Urba, “Adjuvant Immunization of HLA-A2-Positive Melanoma Patients With a Modified gp100 Peptide Induces Peptide-Specific CD8+ T-Cell Responses,” Journal of Clinical Oncology, Vol. 21, No. 1, 2003, pp. 1562-1573. doi:10.1200/JCO.2003.09.020

[48]   E. B. Walker, D. Haley, W. Miller, K. Floyd, K. P. Wisner, N. Sanjuan, H. Maecker, P. Romero, H.-M. Hu, W. G. Alvord, J. W. Smith II, B. A. Fox and W. J. Urba, “Gp100209-2M Peptide Immunization of Human Lymphocyte Antigen-A2+ Stage 1-III Melanoma Patients Induces Significant Increase in Antigen-Specific Effector and Long-Term Memory CD8+ T Cells,” Clinical Cancer Research, Vol. 10, No. 2, 2004, pp. 668-680. doi:10.1158/1078-0432.CCR-0095-03

[49]   F. Garrido, F. Ruiz-Cabello, T. Cabrera, J. J. Perez-Villar, M. Lopez-Botet, M. Duggan-Keen and P. L. Stern, “Implications for Immunosurveillance of Altered HLA Class I Phenotypes in Human Tumours,” Immunology Today, Vol. 18, No. 2, 1997, pp. 89-95. doi:10.1016/S0167-5699(96)10075-X

[50]   N. P. Restifo, F. M. Marincola, Y. Kawakami, J. Taubenberger, J. R. Yannelli and S. A. Rosenberg, “Loss of Functional Beta2-Microglobulin in Metastatic Melanomas from Five Patients Receiving Immunotherapy,” Journal of the National Cancer Institute, Vol. 88, No. 2, 1996, pp. 100-108. doi:10.1093/jnci/88.2.100

[51]   F. V. Cromme, J. Airey, M.-T. Heemels, H. L. Ploegh, P. J. Keating, P. L. Stern, C. J. Meijer and J. M. Walboomers, “Loss of Transporter Protein, Encoded by the TAP1 Gene, Is Highly Correlated with Loss of HLA Expression in Cervical Carcinomas,” The Journal of Experimental Medicine, Vol. 179, No. 1, 1994, pp. 335-340. doi:10.1084/jem.179.1.335

[52]   B. Seliger, M. J. Maeurur and S. Ferrone, “TAP off-Tumors on,” Immunology Today, Vol. 18, No. 6, 1997, pp. 292-299.

[53]   B. Seliger, U. Ritz, R. Abele, M. Bock, R. Tampe, G. Sutter, I. Drexler, C. Huber and S. Ferrone, “Immune Escape of Melanoma: First Evidence of Structural Alterations in Two Distinct Components of the MHC lass I Antigen Processing Pathway,” Cancer Research, Vol. 61, No. 24, 2001, pp. 8647-8650.

[54]   S. Agrawal, K. Reemtsma, E. Bagiella, S. F. Oluwole and N. S. Braunstein, “Role of TAP-1 and/or TAP-2 Antigen Presentation Defects in Tumorigenicity of Mouse Melanoma,” Cellular Immunology, Vol. 228, No. 2, 2004, pp. 130-137. doi:10.1016/j.cellimm.2004.04.006

[55]   L. Lanier, “NK Cell Recognition,” Annual Review of Immunology, Vol. 23, 2005, pp. 225-274. doi:10.1146/annurev.immunol.23.021704.115526

[56]   E. Jager, M. Ringhoffer, J. Karbach, M. Arand, F. Oesch and A. Knuth, “Inverse Relationship of Melanocyte Differentiation Antigen Expression in Melanoma Tissues and CD8+ Cytotoxic-T Cell Responses: Evidence for Immunoselection of Antigen-Loss Variants in Vivo,” International Journal of Cancer, Vol. 66, No. 4, 1996, pp. 470-476. doi:10.1002/(SICI)1097-0215(19960516)66:4<470::AID-IJC10>3.0.CO;2-C

[57]   S. A. Rosenberg, R. M. Sherry, K. E. Morton, W. J. Scharfman, J. C. Yang, S. L. Topalian, R. E. Royal, U. Kammula, N. P. Restifo, M. S. Hughes, D. Schwartzentruber, D. M. Berman, S. L. Schwarz, L. T. Ngo, S. A. Mavroukakis, D. E. White and S. M. Steinberg, “Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma,” The Journal of Immunology, Vol. 175, No. 9, 2005, pp. 6169-6176.

[58]   G. V. Yamshchikov, D. L. Barnd, S. Eastham, H. Galavotti, J. W. Patterson, D. H. Deacon, D. Teates, P. Neese, W. W. Grosh, G. Petroni, V. H. Engelhard and C. L. Slingluff, Jr., “Evaluation of Peptide Vaccine Immunogenicity in Draining Lymph Nodes and Peripheral Blood of Melanoma Patients,” International Journal of Cancer, Vol. 92, No. 5, 2001, pp. 703-711. doi:10.1002/1097-0215(20010601)92:5<703::AID-IJC1250>3.0.CO;2-5

[59]   C. L. Slingluff, Jr., G. R. Petroni, G. V. Yamshchikov, D. L. Barnd, S. Eastham, H. Galavottia, J. W. Patterson, D. H. Deacon, S. Hibbitts, D. Teates, P. Y. Neese, W. W. Grosh, K. A. Chianese-Bullock, E. M. Woodson, C. J. Wiernasz, P. Merrill, J. Gibson, M. Ross and V. H. Engelhard, “Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in GranulocyteMacrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells,” Journal of Clinical Oncology, Vol. 21, No. 21, 2003, pp. 4016-4026. doi:10.1200/JCO.2003.10.005

[60]   C. L. Slingluff, Jr., G. R. Petroni, G. V. Yamshchikov, S. Hibbitts, W. W. Grosh, K. A. Chianese-Bullock, E. A. Bissonette, D. L. Barnd, D. H. Deacon, J. W. Patterson, J. Parekh, P. Y. Neese, E. M. Woodson, C. J. Wiernasz and P. Merrill, “Immunologic and Clinical Outcomes of Vaccination with a Multiepitope Melanoma Peptide Vaccine Plus Low-Dose Interleukin-2 Administered Either Concurrently or on a Delayed Schedule,” Journal of Clinical Oncology, Vol. 22, No. 22, 2004, pp. 4474-4485. doi:10.1200/JCO.2004.10.212

[61]   K. A. Chianese-Bullock, J. Pressley, C. Garbee, S. Hibbitts, C. Murphy, G. Yamshchikov, R. R. Petroni, E. A. Bissonette, P. Y. Neese, W. W. Grosh, P. Merrill, R. Fink, E. M. H. Woodson, C. J. Wiernasz, J. W. Patterson and C. L. Slingluff, Jr., “MAGE-A1-, MAGE-A10-, and gp100-Derived Peptides Are Immunogenic When Combined with Granulocyte-Macrophage Colony-Stimulating Factor and Montanide ISA-51 Adjuvant and Administered as Part of a Multipeptide Vaccine for Melanoma,” The Journal of Immunology, Vol. 174, No. 5, 2005, pp. 3080-3086.

[62]   C. L. Slingluff, Jr., G. R. Petroni, K. A. Chianese-Bullock, M. E. Smolkin, S. Hibbitts, C. Murphy, N. Johansen, W. W. Grosh, G. V. Yamshchikov, P. Y. Neese, J. W. Patterson, R. Fink and P. K. Rehm, “Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting,” Clinical Cancer Research, Vol. 13, No. 21, 2007, pp. 6386-6395. doi:10.1158/1078-0432.CCR-07-0486

[63]   C. L. Slingluff, Jr., G. R. Petroni, W. Olson, A. Czarkowski, W. W. Grosh, M. Smolkin, K. A. Chianese-Bullock, P. Y. Neese, D. H. Deacon, C. Nail, P. Merrill, R. Fink, J. W. Patterson and P. K. Rehm, “Helper T-Cell Responses and Clinical Activity of a Melanoma Vaccine with Multiple Peptides from MAGE and Melanocytic Differentiation Antigens,” Journal of Clinical Oncology, Vol. 26, No. 30, 2008, pp. 4973-4980. doi:10.1200/JCO.2008.17.3161

[64]   C. L. Slingluff, Jr., G. R. Petroni, K. A. Chianese-Bullock, M. E. Smolkin, M. I. Ross, N. B. Haas, M. von Mehren and W. W. Grosh, “Randomized Multicenter Trial of the Effects of Melanoma-Associated Helper Peptides and Cyclophosphamide on the Immunogenicity of a Multipeptide Melanoma Vaccine,” Journal of Clinical Oncology, Vol. 29, No. 21, 2011, pp. 2924-2932. doi:10.1200/JCO.2010.33.8053

[65]   G. Q. Phan, C. E. Touloukian, J. C. Yang, N. P. Restifo, R. M. Sherry, P. Hwu, S. L. Topalian, D. J. Schwart-zentruber, C. A. Seipp, L. J. Freezer, K. E. Morton, S. A. Mavroukakis, D. E. White and S. A. Rosenberg, “Immunization of Patients with Metastatic Melanoma Using Both Class Iand Class II-Restricted Peptides from Melanoma-Associated Antigens,” Journal of Immunotherapy, Vol. 26, No. 4, 2003, pp. 349-356. doi:10.1097/00002371-200307000-00007

[66]   R. P. Sutmuller, L. M. van Duivenvoorde, A. van Elsas, T. N. Shumacher, M. E. Wildenberg, J. P. Allison, R. E. Toes, R. Offringa and C. J. Melief, “Synergism of Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade and Depletion of CD25+ Regulatory T Cells in Suppression of Autoreactive Cytotoxic T Lymphocyte Responses,” The Journal of Experimental Medicine, Vol. 194, No. 6, 2001, pp. 823-832. doi:10.1084/jem.194.6.823

[67]   M. D. Sharma, D.-Y. Hou, Y. Lie, P. A. Koni, R. Metz, P. Chandler, A. L. Mellor, Y. He and D. H. Munn, “Indoleamine 2,3-Dioxygenase Controls Conversion of Foxp3+ Tregs to TH17-Like Cells in Tumor-Draining Lymph Nodes,” Blood, Vol. 113, No. 24, 2009, pp. 6102-6111. doi:10.1182/blood-2008-12-195354

[68]   E. Maraskovsky, S. Sjolander, D. P. Drane, M. Schnurr, T. T. Le, L. Mateo, T. Luft, K. A. Masterman, T. Y. Tai, Q. Chen, S. Green, A. Sjolander, M. J. Pearse, F. A. Lemonnier, W. Chen, J. Cebon and A. Suhrbier, “NY-ESO-1 Protein Formulated in ISCOMATRIX Adjuvant Is a Potent Anticancer Vaccine Inducing Both Humoral and CD8+ T-Cell-Mediated Immunity and Protection against NY-ESO-1+ Tumors,” Clinical Cancer Research, Vol. 10, No. 8, 2004, pp. 2879-2890. doi:10.1158/1078-0432.CCR-03-0245

[69]   I. D. Davis, W. Chen, H. Jackson, P. Parente, M. Shackleton, W. Hopkins, Q. Chen, N. Dimopoulos, T. Luke, R. Murphy, A. M. Scott, E. Maraskovsky, G. McArthur, D. MacGregor, S. Sturrock, T. Y. Tai, S. Green, A. Cuthbertson, D. Maher, L. Miloradovic, S. V. Mitchell, G. Ritter, A. A. Jungbluth, Y. T. Chen, S. Gnjatic, E. W. Hoffman, L. J. Old and J. S. Cebon, “Recombinant NYESO-1 Protein with ISCOMATRIX Adjuvant Induces Broad Integrated Antibody and CD4+ and CD8+ T Cell Responses in Humans,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, No. 29, 2004, pp. 10697-10702. doi:10.1073/pnas.0403572101

[70]   T. Nicholaou, L. M. Ebert, I. D. Davis, G. A. McArthur, H. Jackson, N. Dimopoulos, B. Tan, E. Maraskovsky, L. Miloradovic, W. Hopkins, L. Pan, R. Venhaus, E. W. Hoffman, W. Chen and J. Cebon, “Regulatory T-CellMediated Attenuation of T-Cell Responses to the NYESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma,” Clinical Cancer Research, Vol. 15, No. 6, 2009, pp. 2166-2173. doi:10.1158/1078-0432.CCR-08-2484

[71]   L. M. Ebert, S. E. MacRaild, D. Zanker, I. D. Davis, J. Cebon and W. Chen, “A Cancer Vaccine Induces Expansion of NY-ESO-1-Specific Regulatory T Cells in Patients with Advanced Melanoma,” PLoS One, Vol. 7, No. 10, 2012, Article ID: e48424. doi:10.1371/journal.pone.0048424

[72]   M. W. Schreurs, A. J. de Boer, C. G. Figdor and G. J. Adema, “Genetic Vaccination against the Melanocyte Lineage-Specific Antigen gp100 Induces Cytotoxic T Lymphocyte-Mediated Tumor Protection,” Cancer Research, Vol. 58, No. 12, 1998, pp. 2509-2514.

[73]   M. Bellone, D. Cantarella, P. Castiglioni, M. C. Crosti, A. Ronchetti, M. Moro, M. P. Garancini, G. Casorati and P. Dellabona, “Relevance of the Tumor Antigen in the Validation of Three Vaccination Strategies for Melanoma,” The Journal of Immunology, Vol. 165, No. 5, 2000, pp. 2651-2656.

[74]   L. W. Weber, W. B. Browne, J. D. Wolchok, R. Srinivasan, J. Qin, Y. Moroi, R. Clynes, P. Song, J. J. Lewis, A. N. Houghton, “Tumor Immunity and Autoimmunity Induced by Immunization with Homologous DNA,” The Journal of Clinical Investigation, Vol. 102, No. 6, 1998, pp. 1258-1264. doi:10.1172/JCI4004

[75]   W. B. Browne, R. Srinivasan, J. D. Wolchok, W. G. Hawkins, N. E. Blachere, R. Dyall, J. J. Lewis and A. N. Houghton, “Coupling and Uncoupling of Tumor Immunity and Autoimmunity,” The Journal of Experimental Medicine, Vol. 190, No. 11, 1999, pp. 1717-1722. doi:10.1084/jem.190.11.1717

[76]   S. T. Tagawa, P. Lee, J. Snively, W. Boswell, S. Ounpraseuth, S. Lee, B. Hickingbottom, J. Smith, D. Johnson and J. S. Weber, “Phase I Study of Intranodal Delivery of a Plasmid DNA Vaccine for Patients with Stage IV Melanoma,” Cancer, Vol. 98, No. 1, 2003, pp. 144-154. doi:10.1002/cncr.11462

[77]   J. Weber, W. Boswell, J. Smith, E. Hersh, J. Snively, M. Diaz, X. Lie, M. Obrocea, Z. Qiu and A. Bot, “Phase I Trial of Intranodal Injection of a Melan-A/MART-1 DNA Plasmid Vaccine in Patients with Stage IV Melanoma,” Journal of Immunotherapy, Vol. 31, No. 2, 2008, pp. 215-223. doi:10.1097/CJI.0b013e3181611420

[78]   A. Anichini, A. Scarito, A. Molla, G. Parmiani and R. Mortarini, “Differentiation of CD8+ T Cells from TumorInvaded and Tumor-Free Lymph Nodes of Melanoma Patients: Role of Common Gamma-Chain Cytokines,” The Journal of Immunology, Vol. 171, No. 4, 2003, pp. 2134-2141.

[79]   R. Mortarini, A. Piris, A. Maurichi, A. Molla, I. Bersani, A. Bono, C. Bartoli, M. Santinami, C. Lombardo, F. Ravagnani, N. Cascinelli, G. Parmiani and A. Anichini, “Lack of Terminally Differentiated Tumor-specific CD8+ T Cells at Tumor Site in Spite of Antitumor Immunity to Self-Antigens in Human Metastatic Melanoma,” Cancer Research, Vol. 63, No. 10, 2003, pp. 2535-2545.

[80]   A. Zippelius, P. Batard, V. Rubio-Godoy, G. Bioley, D. Lienard, F. Lejeune, D. Rimoldi, P. Guillaume, N. Meidenbauer, A. Mackensen, N. Rufer, N. Lubenow, D. Speiser, J. C. Cerottini, P. Romero and M. J. Pittet, “Effector Function of Human Tumor-Specific CD8 T Cells in Melanoma Lesions: A State of Local Functional Tolerance,” Cancer Research, Vol. 64, No. 8, 2004, pp. 2865-2873. doi:10.1158/0008-5472.CAN-03-3066

[81]   P. P. Lee, C. Yee, P. A. Savage, L. Fong, D. Brockstedt, J. S. Weber, D. Johnson, S. Swetter, J. Thompson, P. D. Greenberg, M. Roederer and M. M. Davis, “Characterization of Circulating T Cells Specific for Tumor-Associated Antigens in Melanoma Patients,” Nature Medicine, Vol. 5, No. 6, 1999, pp. 677-685. doi:10.1038/9525

[82]   M.-B. Nielsen, V. Monsurro, S. A. Migueles, E. Wang, A. Perez-Diaz, K.-H. Lee, U. Kammula, S. A. Rosenberg and F. M. Marincola, “Status of Activation of Circulating Vaccine-Elicited CD8+ T Cells,” The Journal of Immunology, Vol. 165, No. 4, 2000, pp. 2287-2296.

[83]   L. T. Nguyen, A. R. Elford, K. Murakami, K. M. Garza, S. P. Schoenberger, B. Odermatt, D. E. Speiser and P. S. Ohashi, “Tumor Growth Enhances Cross-Presentation Leading to Limited T Cell Activation without Tolerance,” The Journal of Experimental Medicine, Vol. 195, No. 4, 2002, pp. 423-435. doi:10.1084/jem.20010032

[84]   S. Lorenzi, F. Mattei, A. Sistiqu, L. Bracci, F. Spadaro, M. Sanchez, M. Spada, F. Belardelli, L. Gabriele and G. Schiavoni, “Type I IFNs Control Antigen Retention and Survival of CD8α+ Dendritic Cells after Uptake of Tumor Apoptotic Cells Leading to Cross-Priming,” The Journal of Immunology, Vol. 186, No. 9, 2011, pp. 5142-5150. doi:10.4049/jimmunol.1004163

[85]   T. Cao, H. Ueno, C. Glaser, J. W. Fay, A. K. Palucka and J. Banchereau, “Both Langerhans Cells and Interstitial DC Cross-Present Melanoma Antigens and Efficiently Activate Antigen-Specific CTL,” European Journal of Immunology, Vol. 37, No. 9, 2007, pp. 2657-2667. doi:10.1002/eji.200636499

[86]   J. Banchereau and R. M. Steinman, “Dendritic Cells and the Control of Immunity,” Nature, Vol. 392, No. 6637, 1998, pp. 245-252. doi:10.1038/32588

[87]   C. A. Janeway, Jr. and R. Medzhitov, “Innate Immune Recognition,” Annual Review of Immunology, Vol. 20, 2002, pp. 197-216. doi:10.1146/annurev.immunol.20.083001.084359

[88]   O. Joffre, M. A. Nolte, R. Sporr and C. Reis e Sousa, “Inflammatory Signals in Dendritic Cell Activation and the Induction of Adaptive Immunity,” Immunological Reviews, Vol. 227, No. 1, 2009, pp. 234-247. doi:10.1111/j.1600-065X.2008.00718.x

[89]   A. R. Ferguson, L. A. Nichols, A. L. Zarling, E. D. Thompson, C. C. Brinkman, K. M. Hargadon, T. N. Bullock and V. H. Engelhard, “Strategies and Challenges in Eliciting Immunity to Melanoma,” Immunological Reviews, Vol. 222, No. 1, 2008, pp. 28-42. doi:10.1111/j.1600-065X.2008.00620.x

[90]   A. A. Filatenkov, E. L. Jacovetty, U. B. Fischer, J. M. Curtsinger, M. F. Mescher and E. Ingulli, “CD4 T CellDependent Conditioning of Dendritic Cells to Produce IL-12 Results in CD8-Mediated Graft Rejection and Avoidance of Tolerance,” The Journal of Immunology, Vol. 174, No. 11, 2006, pp. 6909-6917.

[91]   C. S. Schmidt and M. F. Mescher, “Peptide Antigen Priming of Naive, But Not Memory, CD8 T Cells Requires a Third Signal That Can Be Provided by IL-12,” The Journal of Immunology, Vol. 168, No. 11, 2002, pp. 5521-5529.

[92]   A. Alshamsan, S. Hamdy, S. Das, A. Lavasanifar, J. Samuel and A. El-Kadi, “Validation of Bone Marrow Derived Dendritic Cells as an Appropriate Model to Study Tumor-Mediated Suppression of DC Maturation through STAT3 Hyperactivation,” Journal of Pharmacy and Pharmaceutical Sciences, Vol. 13, No. 1, 2010, pp. 21-26.

[93]   K. M. Hargadon, O. A. Forrest and P. R. Reddy, “Suppression of the Maturation and Activation of the Dendritic Cell Line DC2.4 by Melanoma-Derived Factors,” Cellular Immunology, Vol. 272, No. 2, 2012, pp. 275-282. doi:10.1016/j.cellimm.2011.10.003

[94]   K. M. Hargadon, Y. T. Ararso, O. A. Forrest and C. M. Harte, “Melanoma-Associated Suppression of the Dendritic Cell Lines DC2.4 and JAWSII,” American Journal of Immunology, Vol. 8, No. 4, 2012, pp. 179-190.

[95]   D. H. Munn, M. D. Sharma, D. Hou, B. Baban, J. R. Lee, S. J. Antonia, J. L. Messina, P. Chandler, P. A. Koni and A. L. Mellor, “Expression of Indoleamine 2,3-Dioxygenase by Plasmacytoid Dendritic Cells in Tumor-Draining Lymph Nodes,” The Journal of Clinical Investigation, Vol. 114, No. 2, 2004, pp. 280-290.

[96]   M. D. Sharma, D. Y. Hou, Y. Liu, P. A. Koni, R. Metz, P. Chandler, A. L. Mellor, Y. He and D. H. Munn, “Indoleamine 2,3-Dioxygenase Controls Conversion of Foxp3+ Tregs to TH17-Like Cells in Tumor-Draining Lymph Nodes,” Blood, Vol. 113, No. 24, 2009, pp. 6102-6111. doi:10.1182/blood-2008-12-195354

[97]   S. K. Watkins, Z. Zhu, E. Riboldi, K. A. Shafer-Weaver, K. E. Stagliano, M. M. Sklavos, S. Ambs, H. Yagita and A. A. Hurwitz, “FOXO3 Programs Tumor-Associated DCs to Become Tolerogenic in Human and Murine Prostate Cancer,” The Journal of Clinical Investigation, Vol. 121, No. 4, 2011, pp. 1361-1372. doi:10.1172/JCI44325

[98]   R. C. Harris, K. A. Chianese-Bullock, G. R. Petroni, J. T. Schaefer, L. B. Brill II, K. R. Molhoek, D. H. Deacon, J. W. Patterson and C. L. Slingluff, Jr., “The Vaccine-Site Microenvironment Induced by Injection of Incomplete Freund’s Adjuvant, with or without Melanoma Peptides,” Journal of Immunotherapy, Vol. 35, No. 1, 2012, pp. 78-88. doi:10.1097/CJI.0b013e31823731a4

[99]   R. Xiang, H. N. Lode, T.-H. Chao, J. M. Ruehlmann, C. S. Dolman, F. Rodriguez, J. L. Whitton, W. W. Overwijk, N. P. Restifo and R. R. Reisfeld, “An Autologous Oral DNA Vaccine Protects Against Murine Melanoma,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 97, No. 10, 2000, pp. 5492-5497. doi:10.1073/pnas.090097697

[100]   H. Ying, T. Z. Zaks, R. F. Wang, K. R. Irvine, U. S. Kammula, F. M. Marincola, W. W. Leitner and N. P. Restifo, “Cancer Therapy Using a Self-Replicating RNA Vaccine,” Nature Medicine, Vol. 5, No. 7, 1999, pp. 823-827. doi:10.1038/10548

[101]   W. W. Leitner, H. Ying, D. A. Driver, T. W. Dubensky and N. P. Restifo, “Enhancement of Tumor-Specific Immune Response with Plasmid DNA Replicon Vectors,” Cancer Research, Vol. 60, No. 1, 2000, pp. 51-55.

[102]   W. W. Leitner, L. N. Hwang, M. J. de Veer, A. Zhou, R. H. Silverman, B. R. Williams, T. W. Dubensky, H. Ying and N. P. Restifo, “Alphavirus-Based DNA Vaccine Breaks Immunologic Tolerance by Activating Innate Antiviral Pathways,” Nature Medicine, Vol. 9, No. 1, 2003, pp. 33-39. doi:10.1038/nm813

[103]   B. N. Hangalapura, D. Oosterhoff, T. Gupta, J. de Groot, P. G. Wijnands, V. W. van Beusechem, J. den Haan, T. Tuting, A. J. van den Eertwegh, D. T. Curiel, R. J. Scheper and T. D. de Gruijl, “Delivery Route, MyD88 Signaling and Cross-Priming Events Determine the Anti-Tumor Efficacy of an Adenovirus Based Melanoma Vaccine,” Vaccine, Vol. 29, No. 12, 2011, pp. 2313-2321. doi:10.1016/j.vaccine.2011.01.022

[104]   L. Cervantes-Barragan, R. Zust, R. Maier, S. Sierro, J. Janda, F. Levy, D. Speiser, P. Romero, P.-S. Rohrlich, B. Ludewig and V. Thiel, “Dendritic Cell-Specific Antigen Delivery by Coronavirus Vaccine Vectors Induces LongLasting Protective Antiviral and Antitumor Immunity,” mBio, Vol. 1, No. 4, 2010, Article ID: e00171-10.

[105]   B. N. Hangalapura, D. Oosterhoff, S. Aggarwal, P. G. Wijnands, R. van de Ven, S. J. Santegoets, M. P. van den Tol, E. Hoojiberg, A. Pereboev, A. J. van den Eertwegh, D. T. Curiel, R. J. Scheper and T. D. de Gruijl, “Selective Transduction of Dendritic Cells in Human Lymph Nodes and Superior Induction of High-Avidity Melanoma-Reactive Cytotoxic T Cells by a CD40-Targeted Adenovirus,” Journal of Immunotherapy, Vol. 33, No. 7, 2010, pp. 706-715. doi:10.1097/CJI.0b013e3181eccbd4

[106]   S. A. Rosenberg, Y. Zhai, J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, C. A. Seipp, J. H. Einhorn, B. Roberts and D. E. White, “Immunizing Patients with Metastatic Melanoma Using Recombinant Adenoviruses Encoding MART-1 or gp100 Melanoma Antigens,” Journal of the National Cancer Institute, Vol. 90, No. 24, 1998, pp. 1894-1900.

[107]   R. G. Meyer, C. M. Britten, U. Siepmann, B. Petzold, T. A. Sagban, H. A. Lehr, B. Weigle, M. Schmitz, L. Mateo, B. Schmidt, H. Bernhard, T. Jakob, R. Hein, G. Schuler, B. Schuler-Turner, S. N. Wagner, I. Drexler, G. Sutter, N. Arndtz, P. Chaplin, J. Metz, A. Enk, C. Huber and T. Wolfel, “A Phase I Vaccination Study with Tyrosinase in Patients with Stage II Melanoma Using Recombinant Modified Vaccinia Virus Ankara (MVA-hTyr),” Cancer Immunology, Immunotherapy, Vol. 54, No. 5, 2005, pp. 453-467. doi:10.1007/s00262-004-0616-7

[108]   D. Oertli, W. R. Marti, P. Zajac, C. Noppen, T. Kocher, E. Padovan, M. Adamina, R. Schumacher, F. Harder, M. Heberer and G. C. Spagnoli, “Rapid Induction of Specific Cytotoxic T Lymphocytes against Melanoma-Associated Antigens by a Recombinant Vaccinia Virus Vector Expressing Multiple Immunodominant Epitopes and Costimulatory Molecules in Vivo,” Human Gene Therapy, Vol. 13, No. 4, 2002, pp. 569-575. doi:10.1089/10430340252809856

[109]   M. Adamina, R. Rosenthal, W. P. Weber, D. M. Frey, C. T. Viehl, M. Bolli, R. W. Huegli, A. L. Jacob, M. Heberer, D. Oertli, W. Marti, G. C. Spagnoli and P. Zajac, “Intranodal Immunization with a Vaccinia Virus Encoding Multiple Antigenic Epitopes and Costimulatory Molecules in Metastatic Melanoma,” Molecular Therapy, Vol. 18, No. 3, 2010, pp. 651-659. doi:10.1038/mt.2009.275

[110]   P. Zajac, D. Oertli, W. Marti, M. Adamina, M. Bolli, U. Guller, C. Noppen, E. Padovan, E. Schultz-Thater, M. Heberer and G. Spagnoli, “Phase I/II Clinical Trial of a Nonreplicative Vaccinia Virus Expressing Multiple HLA-A0201-Restricted Tumor-Associated Epitopes and Costimulatory Molecules in Metastatic Melanoma Patients,” Human Gene Therapy, Vol. 14, No. 16, 2003, pp. 1497-1510. doi:10.1089/104303403322495016

[111]   M. C. Panelli, J. Wunderlich, J. Jeffries, E. Wang, A. Mixon, S. A. Rosenberg and F. M. Marincola, “Phase 1 Study in Patients with Metastatic Melanoma of Immunization with Dendritic Cells Presenting Epitopes Derived from the Melanoma-Associated Antigens MART-1 and gp100,” Journal of Immunotherapy, Vol. 23, No. 4, 2000, pp. 487-498. doi:10.1097/00002371-200007000-00013

[112]   M. V. Dhodapkar, R. M. Steinman, J. Kravovsky, C. Munz and N. Bhardwaj, “Antigen-Specific Inhibition of Effector T Cell Function in Humans after Injection of Immature Dendritic Cells,” The Journal of Experimental Medicine, Vol. 193, No. 2, 2001, pp. 233-238. doi:10.1084/jem.193.2.233

[113]   L. A. Lambert, G. R. Gibson, M. Maloney, B. Durell, R. J. Noelle and R. J. Barth, Jr., “Intranodal Immunization with Tumor Lysate-Pulsed Dendritic Cells Enhances Protective Antitumor Immunity,” Cancer Research, Vol. 61, No. 2, 2001, pp. 641-646.

[114]   X. Zhang, M. A. Munegowda, J. Yuan, Y. Wei and J. Xiang, “Optimal TLR9 Signal Converts Tolerogenic CD4-8-DCs into Immunogenic Ones Capable of Stimulating Antitumor Immunity via Activating CD4+ Th1/Th17 and NK Cell Responses,” Journal of Leukocyte Biology, Vol. 88, No. 2, 2010, pp. 393-403. doi:10.1189/jlb.0909633

[115]   S. Yang, C. E. Vervaert, J. Burch, Jr., J. Grichnik, H. F. Siegler and T. L. Darrow, “Murine Dendritic Cells Transfected with Human gp100 Elicit Both Antigen-Specific CD8+ and CD4+ T-Cell Responses and Are More Effective than DNA Vaccines at Generating Anti-Tumor Immunity,” International Journal of Cancer, Vol. 83, No. 4, 1999, pp. 532-540. doi:10.1002/(SICI)1097-0215(19991112)83:4<532::AID-IJC16>3.0.CO;2-K

[116]   M. Lotem, Y. Zhao, J. Riley, P. Hwu, R. A. Morgan, S. A. Rosenberg and M. R. Parkhurst, “Presentation of Tumor Antigens by Dendritic Cells Genetically Modified with Viral and Nonviral Vectors,” Journal of Immunotherapy, Vol. 29, No. 6, 2006, pp. 616-627. doi:10.1097/01.cji.0000211312.36363.56

[117]   B. Thurner, I. Haendle, C. Roder, D. Dieckmann, P. Keikavoussi, H. Jonuleit, A. Bender, C. Maczek, D. Schreiner, P. von den Driesch, E. B. Brocker, R. M. Steinman, A. Enk, E. Kampgen and G. Schuler, “Vaccination with Mage-3A1 Peptide-pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage 4 Melanoma,” The Journal of Experimental Medicine, Vol. 190, No. 11, 1999, pp. 1669-1678. doi:10.1084/jem.190.11.1669

[118]   S. Markowicz, Z. I. Nowecki, P. Rutkowski, A. W. Lipkowski, M. Biernacka, A. Jakubowska-Mucka, T. Switaj, A. Misicka, H. Skurzak, H. Polowniak-Pracka and J. Walewski, “Adjuvant Vaccination with Melanoma Antigen-Pulsed Dendritic Cells in Stage III Melanoma Patients,” Medical Oncology, Vol. 29, No. 4, 2012, pp. 2966-2977. doi:10.1007/s12032-012-0168-1

[119]   F. O. Nestle, S. Alijagic, M. Gillier, Y. Sun, S. Grabbe, R. Dummer, G. Burg and D. Schadendorf, “Vaccination of Melanoma Patients with Peptideor Tumor Lysate-Pulsed Dendritic Cells,” Nature Medicine, Vol. 4, No. 3, 1998, pp. 323-332. doi:10.1038/nm0398-328

[120]   M. G. O’Rourke, M. Johnson, C. Lanagan, J. See, J. Yang, J. R. Bell, G. J. Slater, B. M. Kerr, B. Crowe, D. M. Purdie, S. L. Elliott, K. A. Ellem and C. W. Schmidt, “Durable Complete Clinical Responses in a Phase I/II Trial Using an Autologous Melanoma Cell/Dendritic Cell Vaccine,” Cancer Immunology, Immunotherapy, Vol. 52, No. 6, 2003, pp. 387-395.

[121]   R. O. Dillman, A. A. Nanci, S. T. Williams, R. B. Kim, R. L. Hafer, C. L. Coleman, P. C. Wang, C. M. Duma, P. V. Chen, S. R. Selvan, A. N. Cornforth and C. DePriest, “Durable Complete Response of Refractory, Progressing Metastatic Melanoma after Treatment with a Patient-Specific Vaccine,” Cancer Biotherapy & Radiopharmaceuticals, Vol. 25, No. 5, 2010, pp. 553-557. doi:10.1089/cbr.2010.0819

[122]   E. H. Aarntzen, I. J. de Vries, W. J. Lesterhuis, D. Schuurhuis, J. F. Jacobs, K. Bol, G. Schreibelt, R. Mus, J. H. de Wilt, J. B. Haanen, J. D. Schadendorf, A. Croockewit, W. A. Blokx, M. M. van Rossum, W. W. Kwok, G. J. Adema, C. J. Punt and C. G. Figdor, “Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell-Based Vaccination,” Cancer Research, Vol. 73, No. 1, 2013, pp. 19-29. doi:10.1158/0008-5472.CAN-12-1127

[123]   A. Correll, A. Tuettenberg, C. Becker and H. Jonuleit, “Increased Regulatory T-Cell Frequencies in Patients with Advanced Melanoma Correlate with a Generally Impaired T-Cell Responsiveness and Are Restored after Dendritic Cell-Based Vaccination,” Experimental Dermatology, Vol. 19, No. 8, 2010, pp. e213-e221. doi:10.1111/j.1600-0625.2009.01055.x

[124]   T. Iwata-Kajihara, H. Sumimoto, N. Kawamura, R. Ueda, T. Takahashi, H. Mizuguchi, M. Miyagishi, K. Takeda and Y. Kawakami, “Enhanced Cancer Immunotherapy Using STAT3-Depleted Dendritic Cells with High Th1Inducing Ability and Resistance to Cancer Cell-Derived Inhibitory Factors,” The Journal of Immunology, Vol. 187, No. 1, 2011, pp. 27-36. doi:10.4049/jimmunol.1002067

[125]   Y. Nefedova, M. Huang, S. Kusmartsev, R. Bhattacharya, P. Cheng, R. Salup, R. Jove and D. Gabrilovich, “Hyperactivation of STAT3 Is Involved in Abnormal Differentiation of Dendritic Cells in Cancer,” The Journal of Immunology, Vol. 172, No. 1, 2004, pp. 464-474.

[126]   D. I. Gabrilovich, H. L. Chen, K. R. Girgis, H. T. Cunningham, G. M. Meny, S. Nadaf, D. Kavanaugh and D. P. Carbone, “Production of Vascular Endothelial Growth Factor by Human Tumors Inhibits the Functional Maturation of Dendritic Cells,” Nature Medicine, Vol. 2, No. 10, 1996, pp. 1096-1103. doi:10.1038/nm1096-1096

[127]   V. Bronte, D. B. Chappell, E. Apolloni, A. Cabrelle, M. Wang, P. Hwu and N. P. Restifo, “Unopposed Production of Granulocyte-Macrophage Colony-Stimulating Factor by Tumors Inhibits CD8+ T Cell Responses by Dysregulating Antigen-Presenting Cell Maturation,” The Journal of Immunology, Vol. 162, No. 10, 1999, pp. 5728-5737.

[128]   D. Boczkowski, J. Lee and S. Nair, “Dendritic Cells Engineered to Secrete Anti-GITR Antibodies Are Effective Adjuvants to Dendritic Cell-Based Immunotherapy,” Cancer Gene Therapy, Vol. 16, No. 12, 2009, pp. 900-911. doi:10.1038/cgt.2009.39

[129]   S. K. Pruitt, D. Boczkowski, N. de Rosa, N. R. Haley, M. A. Morse, D. S. Tyler, J. Dannull and S. Nair, “Enhancement of Anti-Tumor Immunity through Local Modulation of CTLA-4 and GITR by Dendritic Cells,” European Journal of Immunology, Vol. 41, No. 12, 2011, pp. 3553-3563. doi:10.1002/eji.201141383

[130]   T. H. Han, P. Jin, J. Ren, S. Slezak, F. M. Marincola and D. F. Stroncek, “Evaluation of 3 Clinical Dendritic Cell Maturation Protocols Containing Lipopolysaccharide and Interferon-Gamma,” Journal of Immunotherapy, Vol. 32, No. 4, 2009, pp. 399-407. doi:10.1097/CJI.0b013e31819e1773

[131]   R. Aguilera, C. Saffie, A. Tittarelli, F. E. Gonzalez, M. Ramirez, D. Reyes, C. Pereda, D. Hevia, T. Garcia, L. Salazar, A. Ferreira, M. Hermoso, A. Mendoza-Naranjo, C. Ferrada, P. Garrido, M. N. Lopez and F. Salazar-Onfray, “Heat-Shock Induction of Tumor-Derived Danger Signals Mediates Rapid Monocyte Differentiation into Clinically Effective Dendritic Cells,” Clinical Cancer Research, Vol. 17, No. 8, 2011, pp. 2474-2483. doi:10.1158/1078-0432.CCR-10-2384

[132]   H. Jonuleit, A. Giesecke-Tuettenberg, T. Tuting, B. Thurner-Schuler, T. B. Stuge, L. Paragnik, A. Kandemir, P. P. Lee, G. Schuler, J. Knop and A. H. Enk, “A Comparison of Two Types of Dendritic Cell as Adjuvants for the Induction of Melanoma-Specific T-Cell Responses in Humans Following Intranodal Injection,” International Journal of Cancer, Vol. 93, No. 2, 2001, pp. 243-251. doi:10.1002/ijc.1323

[133]   E. Romano, M. Rossi, G. Ratzinger, M. A. de Cos, D. J. Chung, K. S. Panageas, J. D. Wolchok, A. N. Houghton, P. B. Chapman, G. Heller, J. Yuan and J. W. Young, “Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation in Vitro, Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells in Vivo,” Clinical Cancer Research, Vol. 17, No. 7, 2011, pp. 1984-1997. doi:10.1158/1078-0432.CCR-10-3421

[134]   T. Lesimple, E. M. Neidhard, V. Vignard, C. Lefeuvre, H. Adamski, N. Labarriere, A. Carsin, D. Monnier, B. Collet, G. Clapisson, B. Birebent, I. Philip, L. Toujas, M. Chokri and V. Quillien, “Immunologic and Clinical Effects of Injecting Mature Peptide-Loaded Dendritic Cells by Intralymphatic and Intranodal Routes in Metastatic Melanoma Patients,” Clinical Cancer Research, Vol. 12, No. 24, 2006, pp. 7380-7388. doi:10.1158/1078-0432.CCR-06-1879

[135]   W. J. Lesterhuis, I. J. de Vries, G. Schreibelt, A. J. Lambeck, E. H. Aarntzen, J. F. Jacobs, N. M. Scharenborg, M. W. van de Rakt, A. J. de Boer, S. Croockewit, M. M. van Rossum, R. Mus, W. J. Oyen, O. C. Boerman, S. Lucas, G. J. Adema, C. J. Punt and C. G. Figdor, “Route of Administration Modulates the Induction of Dendritic Cell Vaccine-Induced Antigen-Specific T Cells in Advanced Melanoma Patients,” Clinical Cancer Research, Vol. 17, No. 17, 2011, pp. 5725-5735. doi:10.1158/1078-0432.CCR-11-1261

[136]   L. H. Butterfield, B. Comin-Anduix, L. Vujanovic, Y. Lee, V. B. Dissette, J. Q. Yang, H. T. Vu, E. Seja, D. K. Oseguera, D. M. Potter, J. A. Glaspy, J. S. Economou and A. Ribas, “Adenovirus MART-1-Engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma,” Journal of Immunotherapy, Vol. 31, No. 3, 2008, pp. 294-309. doi:10.1097/CJI.0b013e31816a8910

[137]   J. C. Steele, A. Rao, J. R. Marsden, C. J. Armstrong, S. Berhane, L. J. Billingham, N. Graham, C. Roberts, G. Ryan, H. Uppal, C. Walker, L. S. Young and N. M. Steven, “Phase I/II Trial of a Dendritic Cell Vaccine Transfected with DNA Encoding Melan A and gp100 for Patients with Metastatic Melanoma,” Gene Therapy, Vol. 18, No. 6, 2011, pp. 584-593. doi:10.1038/gt.2011.1

[138]   S. A. Rosenberg, J. R. Yannelli, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn and D. E. White, “Treatment of Patients with Metastatic Melanoma with Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2,” Journal of the National Cancer Institute, Vol. 86, No. 15, 1994, pp. 1159-1166. doi:10.1093/jnci/86.15.1159

[139]   C. Yee, J. A. Thompson, D. Byrd, S. R. Riddell, P. Roche, E. Celis and P. D. Greenberg, “Adoptive T Cell Therapy Using Antigen-Specific CD8+ T Cell Clones for the Treatment of Patients with Metastatic Melanoma: In Vivo Persistence, Migration, and Antitumor Effect of Transferred T Cells,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 99, No. 25, 2002, pp. 16168-16173. doi:10.1073/pnas.242600099

[140]   M. E. Dudley, J. Wunderlich, M. I. Nishimura, D. Yu, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, R. Sherry, S. F. Leitman and S. A. Rosenberg, “Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma,” Journal of Immunotherapy, Vol. 24, No. 4, 2001, pp. 363-373. doi:10.1097/00002371-200107000-00012

[141]   M. E. Dudley, J. R. Wunderlich, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. M. Sherry, F. M. Marincola, S. F. Leitman, C. A. Seipp, L. Rogers-Freezer, K. E. Morton, A. Nahvi, S. A. Mavroukakis, D. E. White and S. A. Rosenberg, “A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma,” Journal of Immunotherapy, Vol. 25, No. 3, 2002, pp. 243-251. doi:10.1097/00002371-200205000-00007

[142]   E. J. Wherry, J. N. Blattman, K. Murali-Krishna, R. van der Most and R. Ahmed, “Viral Persistence Alters CD8 T-Cell Immunodominance and Tissue Distribution and Results in Distinct Stages of Functional Impairment,” Journal of Virology, Vol. 77, No. 8, 2003, pp. 4911-4927. doi:10.1128/JVI.77.8.4911-4927.2003

[143]   A. Mackensen, N. Meidenbauer, S. Vogl, M. Laumer, J. Berger and R. Andreesen, “Phase I Study of Adoptive TCell Therapy Using Antigen-Specific CD8+ T Cells for the Treatment of Patients with Metastatic Melanoma,” Journal of Clinical Oncology, Vol. 24, No. 31, 2006, pp. 5060-5069. doi:10.1200/JCO.2006.07.1100

[144]   M. E. Dudley, L. T. Ngo, J. Westwood, J. R. Wunderlich and S. A. Rosenberg, “T-Cell Clones from Melanoma Patients Immunized against an Anchor-Modified gp100 Peptide Display Discordant Effector Phenotypes,” Cancer Journal, Vol. 6, No. 2, 2000, pp. 69-77.

[145]   M. E. Dudley, J. R. Wunderlich, T. E. Shelton, J. Even and S. A. Rosenberg, “Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients,” Journal of Immunotherapy, Vol. 26, No. 4, 2003, pp. 332-342. doi:10.1097/00002371-200307000-00005

[146]   M. E. Dudley, J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, M. R. Robinson, M. Raffeld, P. Duray, C. A. Seipp, L. Rogers-Freezer, K. E. Morton, S. A. Mavroukakis, D. E. White and S. A. Rosenberg, “Cancer Regression and Autoimmunity in Patients after Clonal Repopulation with Antitumor Lymphocytes,” Science, Vol. 298, No. 5594, 2002, pp. 850-854. doi:10.1126/science.1076514

[147]   R. J. North, “Cyclophosphamide-Facilitated Adoptive Immunotherapy of an Established Tumor Depends on Elimination of Tumor-Induced Suppressor T Cells,” The Journal of Experimental Medicine, Vol. 155, No. 4, 1982, pp. 1063-1074. doi:10.1084/jem.155.4.1063

[148]   S. A. Rosenberg, P. Spiess and R. Lafreniere, “A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes,” Science, Vol. 233, No. 4770, 1986, pp. 1318-1321. doi:10.1126/science.3489291

[149]   E. A. Walter, P. D. Greenberg, M. J. Gilbert, R. J. Finch, K. S. Watanabe, E. D. Thomas and S. R. Riddell, “Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor,” The New England Journal of Medicine, Vol. 333, No. 16, 1995, pp. 1038-1044. doi:10.1056/NEJM199510193331603

[150]   M. Matloubian, R. J. Concepcion and R. Ahmed, “CD4+ T Cells Are Required to Sustain CD8+ Cytotoxic T-Cell Responses During Chronic Viral Infection,” Journal of Virology, Vol. 68, No. 12, 1994, pp. 8056-8063.

[151]   M. E. Dudley, J. R. Wunderlich, J. C. Yang, R. M. Sherry, S. L. Topalian, N. P. Restifo, R. E. Royal, U. Kammula, D. E. White, S. A. Mavroukakis, L. J. Rogers, G. J. Gracia, S. A. Jones, D. P. Mangiameli, M. M. Pelletier, J. Gea-Banacloche, M. R. Robinson, D. M. Berman, A. C. Filie, A. Abati and S. A. Rosenberg, “Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients with Refractory Metastatic Melanoma,” Journal of Clinical Oncology, Vol. 23, No. 10, 2005, pp. 2346-2357. doi:10.1200/JCO.2005.00.240

[152]   M. E. Dudley, J. C. Yang, R. Sherry, M. S. Hughes, R. Royal, U. Kammula, P. F. Robbins, J. Huang, D. E. Citrin, S. F. Leitman, J. Wunderlich, N. P. Restifo, A. Thomasian, S. G. Downey, F. O. Smith, J. Klapper, K. Morton, C. Laurencot, D. E. White and S. A. Rosenberg, “Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens,” Journal of Clinical Oncology, Vol. 26, No. 2, 2008, pp. 5233-5239. doi:10.1200/JCO.2008.16.5449

[153]   S. A. Rosenberg and M. E. Dudley, “Adoptive Cell Therapy for the Treatment of Patients with Metastatic Melanoma,” Current Opinion in Immunology, Vol. 21, No. 2, 2009, pp. 233-240. doi:10.1016/j.coi.2009.03.002

[154]   S. A. Rosenberg, J. C. Yang, R. M. Sherry, U. S. Kammula, M. S. Hughes, G. Q. Phan, D. E. Citrin, N. P. Restifo, P. F. Robbins, J. R. Wunderlich, K. E. Morton, C. M. Laurencot, S. M. Steinberg, D. E. White and M. E. Dudley, “Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy,” Clinical Cancer Research, Vol. 17, No. 13, 2011, pp. 4550-4557. doi:10.1158/1078-0432.CCR-11-0116

[155]   S. P. Kerkar, L. Sanchez-Perez, S. Yang, Z. Borman, P. Muranski, Y. Ji, D. Chinnasamy, A. D. Kaiser, C. Hinrichs, C. S. Klebanoff, C. D. Scott, L. Gattinoni, R. A. Morgan, S. A. Rosenberg and N. P. Restifo, “Genetic Engineering of Murine CD8+ and CD4+ T Cells for Pre-clinical Adoptive Immunotherapy Studies,” Journal of Immunotherapy, Vol. 34, No. 4, 2011, pp. 343-352. doi:10.1097/CJI.0b013e3182187600

[156]   J. D. Abad, C. Wrzensinski, W. Overwijk, M. A. de Witte, A. Jorritsma, C. Hsu, L. Gattinoni, C. J. Cohen, C. M. Paulos, D. C. Palmer, J. B. Haanen, T. N. Schumacher, S. A. Rosenberg, N. P. Restifo and R. A. Morgan, “T-Cell Receptor Gene Therapy of Established Tumors in a Murine Melanoma Model,” Journal of Immunotherapy, Vol. 31, No. 1, 2008, pp. 1-6. doi:10.1097/CJI.0b013e31815c193f

[157]   R. A. Morgan, M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. D. Kammula, N. P. Restifo, Z. Zheng, A. Nahvi, C. R. de Vries, L. J. Rogers-Freezer, S. A. Mavroukakis and S. A. Rosenberg, “Cancer Regression in Patients after Transfer of Genetically Engineered Lymphocytes,” Science, Vol. 314, No. 5796, 2006, pp. 126-129. doi:10.1126/science.1129003

[158]   L. A. Johnson, R. A. Morgan, M. E. Dudley, L. Cassard, J. C. Yang, M. S. Hughes, U. S. Kammula, R. E. Royal, R. M. Sherry, J. R. Wunderlich, C.-C. R. Lee, N. P. Restifo, S. L. Schwarz, A. P. Cogdill, R. J. Bishop, H. Kim, C. C. Brewer, S. F. Rudy, C. van Waes, J. L. Davis, A. Mathur, R. T. Ripley, D. A. Nathan, C. M. Laurencot and S. A. Rosenberg, “Gene Therapy with Human and Mouse T-Cell Receptors Mediates Cancer Regression and Targets Normal Tissues Expressing Cognate Antigen,” Blood, Vol. 114, No. 3, 2009, pp. 535-546. doi:10.1182/blood-2009-03-211714

[159]   Q. Zhou, I. C. Schneider, I. Edes, A. Honegger, P. Bach, K. Schonfeld, A. Schambach, W. S. Wels, S. Kneissl, W. Uckert and C. J. Buchholz, “T-Cell Receptor Gene Transfer Exclusively to Human CD8+ Cells Enhances Tumor Cell Killing,” Blood, Vol. 120, No. 22, 2012, pp. 4334-4342. doi:10.1182/blood-2012-02-412973

[160]   B. A. Pockaj, R. M. Sherry, J. P. Wei, J. R. Yannelli, C. S. Carter, S. F. Leitman, J. A. Carasquillo, S. M. Steinberg, S. A. Rosenberg and J. C. Yang, “Localization of 111Indium-Labeled Tumor Infiltrating Lymphocytes to Tumor in Patients Receiving Adoptive Immunotherapy. Augmentation with Cyclophosphamide and Correlation with Response,” Cancer, Vol. 73, No. 6, 1994, pp. 1731-1737. doi:10.1002/1097-0142(19940315)73:6<1731::AID-CNCR2820730630>3.0.CO;2-H

[161]   M. H. Kershaw, G. Wang, J. A. Westwood, R. K. Pachynski, H. L. Tiffany, F. M. Marincola, E. Wang, H. A. Young, P. M. Murphy and P. Hwu, “Redirecting Migration of T Cells to Chemokine Secreted from Tumors by Genetic Modification with CXCR2,” Human Gene Therapy, Vol. 13, No. 16, 2002, pp. 1971-1980. doi:10.1089/10430340260355374

[162]   D. J. Waugh and C. Wilson, “The Interleukin-8 Pathway in Cancer,” Clinical Cancer Research, Vol. 14, No. 21, 2008, pp. 6735-6741. doi:10.1158/1078-0432.CCR-07-4843

[163]   W. Peng, Y. Ye, B. A. Rabinovich, C. Liu, Y. Lou, M. Zhang, M. Whittington, Y. Yang, W. W. Overwijk, G. Lizee and P. Hwu, “Transduction of Tumor-Specific T cells with CXCR2 Chemokine Receptor Improves the Migration to Tumor and Antitumor Immune Responses,” Clinical Cancer Research, Vol. 16, No. 22, 2010, pp. 5458-5468. doi:10.1158/1078-0432.CCR-10-0712

[164]   J. A. Craddock, A. Lu, A. Bear, M. Pule, M. K. Brenner, C. M. Rooney and A. E. Foster, “Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b,” Journal of Immunotherapy, Vol. 33, No. 8, 2010, pp. 780-788. doi:10.1097/CJI.0b013e3181ee6675

[165]   E. K. Moon, C. Carpenito, J. Sun, L. C. Wang, V. Kapoor, J. Predina, D. J. Powel, Jr., J. L. Riley, C. H. June and S. M. Albelda, “Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T Cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor,” Clinical Cancer Research, Vol. 17, No. 14, 2011, pp. 4719-4730. doi:10.1158/1078-0432.CCR-11-0351

[166]   T. L. Darrow, Z. Wahab, M. A. Quinn-Allen and H. F. Seigler, “Human Melanoma-Mediated Inhibition of Autologous CD4+ Helper Tumor-Infiltrating Lymphocyte Growth in Vitro,” Cancer, Vol. 69, No. 7, 1992, pp. 1843-1849. doi:10.1002/1097-0142(19920401)69:7<1843::AID-CNCR282069072 8>3.0.CO;2-D

[167]   V. Singh, Q. Ji, L. Feigenbaum, R. M. Leighty and A. A. Hurwitz, “Melanoma Progression despite Infiltration by in Vivo-Primed TRP-2 Specific T Cells,” Journal of Immunotherapy, Vol. 32, No. 2, 2009, pp. 129-139. doi:10.1097/CJI.0b013e31819144d7

[168]   M. Ahmadzadeh, L. A. Johnson, B. Heemskerk, J. R. Wunderlich, M. E. Dudley, D. E. White and S. A. Rosenberg, “Tumor Antigen-Specific CD8 T Cells Infiltrating the Tumor Express High Levels of PD-1 and Are Functionally Impaired,” Blood, Vol. 114, No. 8, 2009, pp. 1537-1544. doi:10.1182/blood-2008-12-195792

[169]   K. Bachmaier, C. Krawczyk, I. Kozieradzki, Y. Y. Kong, T. Sasaki, A. Oliviera-dos-Santos, S. Mariathasan, D. Bouchard, A. Wakeham, A. Itie, J. Le, P. S. Ohashi, I. Sarosi, H. Nishina, S. Lipkowitz and J. M. Penninger, “Negative Regulation of Lymphocyte Activation and Autoimmunity by the Molecular Adaptor Cbl-b,” Nature, Vol. 403, No. 6766, 2000, pp. 211-216. doi:10.1038/35003228

[170]   Y. J. Chiang, H. K. Kole, K. Brown, M. Naramura, S. Fukuhara, F. J. Hu, I. K. Jang, J. S. Gutkind, E. Shevach and H. Gu, “Cbl-b Regulates the CD28 Dependence of T-Cell Activation,” Nature, Vol. 403, No. 6766, 2000, pp. 216-220. doi:10.1038/35003235

[171]   E. A. Wohlfert, L. Gorelik, R. Mittler, R. A. Flavell and R. B. Clark, “Cutting Edge: Deficiency in the E3 Ubiquitin Ligase Cbl-b Results in a Multifunctional Defect in T Cell TGF-Beta Sensitivity in Vitro and in Vivo,” The Journal of Immunology, Vol. 176, No. 3, 2006, pp. 1316-1320.

[172]   R. Hinterleitner, T. Gruber, C. Pfeifhofer-Obermair, C. Lutz-Nicoladoni, A. Tzankov, M. Schuster, J. M. Penninger, H. Loibner, G. Lametschwandtner, D. Wolf and G. Baier, “Adoptive Transfer of siRNA Cblb-Silenced CD8+ T Lymphocytes Augments Tumor Vaccine Efficacy in a B16 Melanoma Model,” PLoS One, Vol. 7, No. 9, 2012, Article ID: e44295. doi:10.1371/journal.pone.0044295

[173]   K. Iwamura, T. Kato, Y. Miyahara, H. Naota, J. Mineno, H. Ikeda and H. Shiku, “SiRNA-Mediated Silencing of PD-1 Ligands Enhances Tumor-Specific Human T-Cell Effector Functions,” Gene Therapy, Vol. 19, No. 10, 2012, pp. 959-966. doi:10.1038/gt.2011.185

[174]   C. Hsu, M. S. Hughes, Z. Zheng, R. B. Bray, S. A. Rosenberg and R. A. Morgan, “Primary Human T Lymphocytes Engineered with a Codon-Optimized IL-15 Gene Resist Cytokine Withdrawal-Induced Apoptosis and Persist Long-Term in the Absence of Exogenous Cytokine,” The Journal of Immunology, Vol. 175, No. 11, 2005, pp. 7226-7234.

[175]   J. Charo, S. E. Finkelstein, N. Grewal, N. P. Restifo, P. F. Robbins and S. A. Rosenberg, “Bcl-2 Overexpression Enhances Tumor-Specific T-Cell Survival,” Cancer Research, Vol. 65, No. 5, 2005, pp. 2001-2008. doi:10.1158/0008-5472.CAN-04-2006

[176]   M. T. Stephan, V. Ponomarev, R. J. Brentjens, A. H. Chang, K. V. Dobrenkov, G. Heller and M. Sadelain, “T Cell-Encoded CD80 and 4-1BBL Induce Autoand Transcostimulation, Resulting in Potent Tumor Rejection,” Nature Medicine, Vol. 13, No. 12, 2007, pp. 1440-1449. doi:10.1038/nm1676

 
 
Top